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Abstract Multinucleated giant cells (MGCs) are often
detected in cases of papillary thyroid carcinoma (PTC).
Their origin and signiﬁcance, however, has not been
established. One possibility is that they form in response to
injury induced by ﬁne needle aspiration biopsy (FNAB).
Other hypotheses are that the chemically-altered colloid
produced by PTC induces MGCs to act as colloidophages,
or else MGCs are a non-speciﬁc immune response ingest-
ing neoplastic follicle cells. We assigned 172 cases of PTC
a semi-quantitative score for MGCs. Cases with ‘‘many’’
MGCs were immunohistochemically stained for AEI/AE-
III, CD68, and CD163 to assess for epithelial vs histiocytic
differentiation, and for thyroglobulin and TTF-1 to assess
for MGC ingestion of colloid or thyroid follicle cells
respectively. Overall, we identiﬁed MGCs in 100/172
(58.1%) PTC specimens; in 45 (26.2%), ‘‘many’’ MGCs
were found, while in 55 (31.9%) MGCs were ‘‘few.’’ The
mean sizes of PTC in cases with many as opposed to rare/
no MGCs was 2.50 cm vs 1.8 [P = 0.003]. The cases of
PTC with many MGCs had higher multifocality (26/45 vs
51/127 [P = 0.06]), extrathyroidal extension (21/45 vs 36/
127 [P = 0.03]), and recurrence (8/45 vs 9/127
[P = 0.08]), than did cases with rare or no MGCs. The
majority of patients both with and without numerous
MGCs had previous histories of FNA or hemilobectomy:
40/45 and 99/127 respectively (P = 0.062). The majority
of MGCs were positive for CD68 (45/45), CD163 (44/45),
thyroglobulin (34/45) and negative for AEI/AEIII (44/45)
and TTF-1 (44/45). These results indicate that MGCs in
PTC are of histiocytic origin. Cases of PTC with many
MGCs have a signiﬁcantly greater likelihood of extrathy-
roidal extension and greater tumor size than cases with
few/no MGCs. MGCs appear to be functioning largely as
colloidophages.
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Introduction
Multinucleated giant cells (MGCs) are often associated
with papillary thyroid carcinoma (PTC). While their pres-
ence has been well-documented in cytologic preparations,
there are relatively few studies of MGCs in histologic
sections of PTC. Estimates of the prevalence of MGCs in
histologic specimens vary widely from 46% to 100%, and
their origin has not been well-established [1–3]. One pos-
sible explanation for the presence of MGCs in PTC is that
they form as a response to prior ﬁne needle aspiration
biopsy (FNAB): patients with thyroid malignancies com-
monly undergo a diagnostic FNAB prior to surgery, and
MGCs may be induced by the subsequent degeneration and
inﬂammation of the surrounding follicular epithelium.
Another explanation is that MGCs form in response to the
abnormal colloid produced by PTCs. Previous studies have
suggested that the colloid secreted by PTC is biochemically
different than that secreted by the normal thyroid [4, 5]. A
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immune response to the carcinoma itself, and act as
phagocytes ingesting the malignant follicle cells. MGCs in
the thyroid are not speciﬁc for PTC: they can be found in
benign thyroid diseases such as Hashimoto’s, De Quer-
vain’s, or palpation thyroiditis, as well as in other
malignancies such as follicular and anaplastic carcinoma
[1, 2, 6, 7]. The prognostic signiﬁcance of MGCs in PTC is
uncertain. In the current study, we evaluated 172 cases of
PTC for the presence of MGCs, scoring them in a semi-
quantitative fashion. Those cases with many MGCs were
correlated with clinicopathologic parameters including
patient age at diagnosis, tumor median size, extrathyroidal
extension, recurrence, multifocality to assess for possible
prognostic signiﬁcance of MGCs in PTC. We also per-
formed a panel of immunohistochemical stains to better
elucidate the origin and nature of MGCs in PTC, including
antibodies to epithelial, histiocytic, and thyroid markers.
Materials and Methods
Study Population and Histopathological Evaluation
Having obtained University of Vermont Institutional
Review Board approval, a total of 172 cases of papillary
thyroid carcinoma were retrieved following computer
diagnostic search from the archives of Fletcher Allen
Health Care. The cases were diagnosed between the years
of 1989–2003 on either complete thyroidectomy or thyroid
lobectomy specimens from a total of 168 patients. Five
patients had initial lobectomies or hemilobectomies, and
subsequent completion surgeries. In four of these cases, we
were able to examine the initial as well as ﬁnal surgical
specimens. Patients ranged in age from 9 to 82 years with a
male to female ratio of 51:117. The histologic diagnosis
was rendered on the basis of previously well-established
nuclear criteria, including enlargement, elongation,
crowding, irregular contours, grooves, pseudoinclusions,
chromatin clearing with peripheral margination, and
multiple macronucleoli, as well as architectural features
[8, 9]. No histopathological variants of papillary thyroid
carcinoma were excluded. All cases with diagnoses other
than papillary carcinoma or follicular variant of papillary
carcinoma were carefully reviewed; in order to be desig-
nated as a variant, tumors were required to predominantly
manifest variant histopathologic features as speciﬁed by
the 2004 World Health Organization criteria [9]. Ulti-
mately, cases included a total of 43 follicular variants, two
oncocytic variants, one diffuse sclerosing variant, and one
columnar cell variant. The remaining 125 cases were
simply diagnosed as papillary thyroid carcinoma. An
average of four hematoxylin and eosin stained slides were
examined per case by two pathologists concurrently. When
assessing slides for the presence of MGCs, certain strict
histologic criteria were employed (Fig. 1).
1. MGCs needed to be located within cystic spaces.
2. They must have glossy dense eosinophilic cytoplasm
(either with or without hemosiderin or vacuoles) [6,
10].
3. There must be at least three randomly assorted nuclei.
Important exclusionary criteria for MGCs included the
presence of ﬁbrovascular cores or any nuclear features
suggestive of PTC, such as nuclear grooves or chromatin
clearing with peripheral margination (Fig. 2). Any one of
these features was considered indicative of a sloughed
papillae and was deemed sufﬁcient cause to exclude the
entity from consideration as an MGC.
A semi-quantitative score was assigned as follows: 0
MGCs per slide = none, 1–2 MGCs per slide in areas of
greatest density = few, C3 MGCs per slide in area of
greatest density = many.
Immunohistochemistry
Immunohistochemical stains were performed on sections
cut from formalin-ﬁxed, parafﬁn-embedded papillary thy-
roid carcinoma cases with ‘‘many’’ MGCs. In order to
distinguish the origin of MGCs, we utilized mouse
Fig. 1 Papillary thyroid
carcinoma. Multinucleated giant
cells are present within cystic
spaces. Characteristic features
include dense eosinophilic
cytoplasm, well-demarcated
borders, and a profusion of
randomly assorted nuclei (a–b)
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AE1/AE3, Dako #M3513, used at a dilution of 1:800) as
well as to histiocytic markers, CD68 (clone KP1, Dako,
used at a dilution of 1:1600) and CD163 (clone 10D6,
Vector Laboratories #VP-C374, used at a dilution of 1:20).
In order to assess the function of MGCs, we utilized mouse
monoclonal antibodies to Thyroglobulin (clone DAK Tg6,
Dako #M0781, used at a dilution of 1:4000) and Thyroid
Transcription Factor 1 (TTF-1) (clone SPT24, Vector
Laboratories #VP-T483, used at a dilution of 1:100). Our
negative control consisted of IgG1 (Dako #X0931 used at a
dilution of 1:50). We performed antigen retrieval in a cit-
rate buffer at a pH of 6.1 (Dako #S1699) by incubation at
98C for 20 min. All primary antibodies were incubated for
30 min at room temperature and were detected using the
the EnVison
TM ? Dual Link kit (Dako #K4065) with DAB
staining.
MGCs displaying a granular cytoplasmic staining pat-
tern for CD68 and/or CD163 were interpreted as being of
histiocytic origin; whereas, MGCs staining positively for
AEI/AEIII were interpreted as being of epithelial origin.
MGCs displaying cytoplasmic positivity for thyroglobulin
were interpreted as having ingested colloid; whereas,
MGCs showing nuclear positivity for TTF-1 were inter-
preted as having ingested follicular cells.
Statistical Analysis
All statistical analysis was performed with SAS version 9
(SAS Institute Inc., Cary, NC). Descriptive statistics were
used to report our ﬁndings. The prevalence of MGCs was
reported as a proportion with its exact binomial conﬁdence
interval. Tumor characteristics among cases with and
without MGCs were reported as frequencies for each cat-
egory. Fisher’s exact test was used to compare cases with
and without MGCs when the variables were categorical.
The Mann–Whitney test was employed when variables
were ordinal, i.e., tumor size. The t-test was used for the
age comparison.
Results
MGCs were identiﬁed in 100/172 (58.1%, 95% CI: 50.4%,
65.6%) PTC specimens; in 45 (26.2%, 95% CI: 19.8%,
33.4%), ‘‘many’’ MGCs were found, while in 55 (31.9%,
95% CI: 25.1%, 39.5%) MGCs were ‘‘few’’ (Table 1). Of
the four patients in which both initial as well as subsequent
lobectomy/hemilobectomy specimens were examined, all
had few to no MGCs. MGCs tended to be located in cystic
spaces or else within follicles, both of which are regions of
Fig. 2 Common histologic
entities that can mimic
multinucleated giant cells.
Sloughed papillae, which can be
distinguished by the presence of
ﬁbrovascular cores and/or
nuclear features of papillary
thyroid carcinoma (a). Grouped
histiocytes, which can be
distinguished by the lack of a
well-deﬁned communal border
(b). Colloid containing
degenerated nuclei, which can
be distinguished by the ill-
deﬁned borders which tend to
replicate the shape of the cyst as
well as the hyperchromatic
attenuated nuclei
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sisted of a mixture of papillary (n = 39) and follicular
variant of papillary (n = 6) histology. In cases with few or
no MGCs, the most common histologic pattern was also
papillary (n = 86), followed by follicular variant (n = 37).
Other variants included oncocytic (n = 2), diffuse scle-
rosing (n = 1), and columnar (n = 1). Overall, follicular
variants of papillary thyroid carcinoma were far more
likely to show few or no MGCs than many: 37/43 (86.0%,
95% CI: 72%, 95%) vs 6/43 (14.0%, 95% CI: 5%, 28%).
The average age of patients with numerous as opposed to
rare/none MGCs was 42.2 (range 20–82) vs 43.7 (range 9–
82) years. This difference was not statistically signiﬁcant
[P = 0.57]. The mean sizes of PTC in cases with many as
opposed to rare/no MGCs was 2.50 cm (range 0.2–9.0 cm)
vs 1.76 (range 0.01–5.2 cm) [P = 0.0025]. The cases of
PTC with many MGCs had higher multifocality (26/45 vs
51/127 [P = 0.055]), extrathyroidal extension (21/45 vs
36/127 [P = 0.028]), and recurrence (8/45 vs 9/127
[P = 0.076]), than did cases with rare or no MGCs. The
majority of patients both with and without numerous
MGCs had previous histories of FNA or hemilobectomy:
40/45 and 99/127 respectively [P = 0.073]. Immunohis-
tochemistry performed on cases of PTC with numerous
MGCs revealed the majority of MGCs to be positive for
CD68 (45/45), CD163 (44/45), thyroglobulin (34/45) and
negative for AEI/AEIII (44/45) and TTF-1 (44/45) (Fig. 3).
Discussion
The results of this study indicate that MGCs can be found
in at least half of PTC cases (100/172; 58.1%), and that
they are most likely of histiocytic rather than epithelial
origin. The majority of MGCs demonstrated a granular
cytoplasmic staining pattern for both histiocytic markers
CD68 (45/45) and CD163 (44/45) and were negative for
epithelial marker AEI/AEIII (44/45). This ﬁnding agrees
with those of previous studies. Guiter et al. examined 76
cases of PTC, and found MGCs in histologic sections in
46% (35/76). A panel of immunohistochemical stains was
performed on ten of the cases: MGCs were uniformly
Table 1 Clinicopathologic features of papillary thyroid carcinoma cases with many versus few/no multinucleated giant cells
Many MGCS (N = 45) Few/No MGCS (N = 127) Statistical signiﬁcance
Average patient age at diagnosis 42.2 years (range: 20–82) 43.7 years (range: 9–82) P = 0.57
Median tumor size 2.5 cm (range: 0.2–9.0) 1.8 cm (range: 0.01–5.2) P = 0.003
Tumor multifocality 26 (57.8%) 51 (40.2%) P = 0.06
Extrathyroidal extension of tumor 21 (46.7%) 36 (28.3%) P = 0.03
Tumor recurrence 8 (17.8%) 9 (7.1%) P = 0.08
Prior FNA or hemilobectomy 40 (88.9%) 99 (78.0%) P = 0.62
Fig. 3 Multinucleated giant cells showed a cytoplasmic staining pattern for CD68 (a), CD163 (b), and Thyroglobulin (c) in the majority of
cases. They showed a lack of cytoplasmic and nuclear positivity for AEI/AEIII (d) and TTF-1 (e) respectively
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lysozyme, KP1/CD68, and alpha-1-antichymotrypsin–
indicating a histiocytic rather than epithelial origin. Tab-
bara et al. compared ten cases of PTC, eight cases of
follicular variant of PTC, and 11 cases of follicular ade-
nomas. MGCs were present in 100% of cases of PTC, 63%
of follicular variant cases, and 0% of follicular adenomas.
Immunohistochemistry was performed on 15 cases with
MGCs; however, not all immunostained sections ultimately
contained MGCs. Of those sections which did, all MGCs
were negative for epithelial markers EMA and AEI/AEIII,
and the majority were positive for one or more histiocytic
markers.
Unlike Tabbara et al., our results indicate that MGCs in
PTC function primarily as colloidophages. The majority
demonstrated cytoplasmic positivity for thyroglobulin (34/
45; 75.6%), and the dense, glossy, eosinophilic appearance
of the cytoplasm was reminiscent of colloid. Also, MGCs
tended to be located either within cystically dilated spaces
or else within follicles, both of which are regions of colloid
deposition. It seems likely that the chemically altered
colloid produced in PTC plays a role in generating the
MGC reaction. There appears to be no linkage between the
injury induced by previous FNA and the appearance of
MGCs, as the majority of patients both with and without
‘‘many’’ MGCs had histories of prior FNA and/or hemi-
lobectomy. There also appears to be no evidence to support
the theory that MGCs act as a non-speciﬁc immune
response, ingesting malignant follicle cells. Thyroid fol-
licular cells normally express TTF-1 in an intranuclear
staining pattern. In only one case in our series did MGCs
show intranuclear positivity for TTF-1, suggesting follic-
ular cell phagocytosis.
Wefoundthattherewasadeﬁniteprognosticsigniﬁcance
to having ‘‘many’’ MGCs in PTC. Those cases of PTC with
many MGCs were statistically more likely to have extra-
thyroidal extension (P = 0.028) and greater tumor size
(P = 0.0025) at surgical resection than those with few/no
MGCs. We speculate that this may be attributable to the fact
that larger tumors more frequently have cystically dilated
spaces. The resulting larger amount of colloid deposition
could stimulate greater than average MGC colloidophagy.
Interestingly, cases of the follicular variant of PTC, which
tend to be composed of small to moderate-sized follicles
rather than cystically dilated spaces, had a far lower likeli-
hoodofhaving‘‘many’’MGCsthandidcasesofnon-variant
PTC. While not statistically signiﬁcant, we did see a trend
in which cases with ‘‘many’’ MGCs showed a greater
probability of multifocality and recurrence than cases with
few/noMGCs (P = 0.055 and P = 0.076 respectively). We
found no clinicopathologic correlation between average
patient age at diagnosis and the presence of MGCs.
To our knowledge, this study represents the most com-
prehensive analysis of MGCs in PTC to date. Although
MGCs have long been known as associated features of
PTC, their signiﬁcance was uncertain. Our results, how-
ever, suggest that the ﬁnding of multiple MGCs may be an
important prognostic indicator and that cases of PTC
should therefore be carefully screened for their presence. In
cases of multiple MGCs, a more aggressive surgical
approach and/or more careful post-surgical follow-up may
be merited.
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